title: Angiotensin-II-dependent changes in alpha-1 adrenoceptor vascular expression in pregnant rats.
abstract: Vessels from pregnant animals show a blunted response to adrenergic agonists. In this work, we explored if pregnancy reduces alpha(1)-adrenergic receptor (alpha(1)-AR)-mediated vascular smooth muscle protein expression as well as agonist-induced contraction in rat aorta, and if angiotensin II (Ang II) levels during pregnancy are related to these changes. Female Wistar rats were divided randomly into nonpregnant (NP) and pregnant groups (first week: P1, second week: P2, third week: P3). Subsets of animals were treated with captopril (5 mg kg(-1) day(-1) for 7 days; n = 6). Phenylephrine (PHE) concentration-response curves were constructed (1 x 10(-9) to 3.1 x 10(-5) mol/l) and alpha(1A)-, alpha(1B)- and alpha(1D)-AR were measured in the aorta by immunoblot. Captopril decreased alpha-AR expression in the NP group. In contrast, pregnancy decreased alpha(1A)-, alpha(1B)- and alpha(1D)-AR levels and captopril prevented this reduction. PHE sensitivity was decreased in the thoracic and abdominal aorta in the P2 group, with no changes in E(max ), and E(max) was decreased in the abdominal aorta in all experimental groups. Our results suggest that Ang II levels during pregnancy are related to a decrease in aortic alpha(1)-AR expression. The physiological meaning of this finding remains to be established.
authors.affiliation: Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina del IPN, México, DF, 11340 México.
authors.forename: Pedro
authors.initials: P
authors.lastname: López-Sánchez
authors.forename: Ismael Bracho
authors.initials: IB
authors.lastname: Valdés
authors.forename: Daniel
authors.initials: D
authors.lastname: Godínez-Hernández
authors.forename: Rosa A
authors.initials: RA
authors.lastname: Bobadilla-Lugo
mesh_terms: D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000804:Angiotensin II / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D001012:Aorta, Abdominal / Q000187:drug effects / Q000378:metabolism*; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism*; D015153:Blotting, Western; D002216:Captopril / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005260:Female; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D010656:Phenylephrine / Q000494:pharmacology; D011247:Pregnancy / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000096:biosynthesis*; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D000316:Adrenergic alpha-Agonists; D018340:Receptors, Adrenergic, alpha-1; D000804:Angiotensin II; D010656:Phenylephrine; D002216:Captopril